MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

[1]  S. Loi,et al.  The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. , 2018, Cancer discovery.

[2]  Zhe Zhang,et al.  Abstract CT039: Cyclin E1 (CCNE1)expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial , 2018, Clinical Trials.

[3]  G. Getz,et al.  Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). , 2018 .

[4]  O. Cohen,et al.  Abstract PD4-01: The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER+ breast cancer , 2018 .

[5]  A. Iafrate,et al.  Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  M. Goetz,et al.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Chiappetta,et al.  CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation , 2017, EMBO molecular medicine.

[8]  A. Bardia,et al.  Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer , 2017 .

[9]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Hudis,et al.  MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[11]  Carlos L. Arteaga,et al.  Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. , 2017, Cancer research.

[12]  J. Wragg,et al.  Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors. , 2017, Cancer research.

[13]  S. Chandarlapaty,et al.  Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence , 2016, Oncogene.

[14]  O. Elemento,et al.  PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy , 2016 .

[15]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[16]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[17]  A. Welm,et al.  Plasma exosome microRNAs are indicative of breast cancer , 2016, Breast Cancer Research.

[18]  G. Shapiro,et al.  A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas , 2016, Clinical Cancer Research.

[19]  H. Ditzel,et al.  High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer , 2016, Clinical Cancer Research.

[20]  Dennis Wang,et al.  Combenefit: an interactive platform for the analysis and visualization of drug combinations , 2016, Bioinform..

[21]  M. Dowsett,et al.  Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. , 2016, Cancer research.

[22]  S. Loi,et al.  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.

[23]  Neville E. Sanjana,et al.  Improved vectors and genome-wide libraries for CRISPR screening , 2014, Nature Methods.

[24]  N. Cloonan,et al.  Profiling direct mRNA-microRNA interactions using synthetic biotinylated microRNA-duplexes , 2014, bioRxiv.

[25]  S. De,et al.  MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability , 2014, eLife.

[26]  C. Mason,et al.  Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1 , 2013, Cell cycle.

[27]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[28]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[29]  M. Korc,et al.  Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells , 2012, Molecular Cancer Therapeutics.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[31]  Charles M. Perou,et al.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.

[32]  Simon C Watkins,et al.  Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. , 2012, Blood.

[33]  Xavier Estivill,et al.  A non-biased framework for the annotation and classification of the non-miRNA small RNA transcriptome , 2011, Bioinform..

[34]  R. Pestell,et al.  Examining the role of cyclin D1 in breast cancer. , 2011, Future oncology.

[35]  G. Hu,et al.  CDK6 kinase activity is required for thymocyte development. , 2011, Blood.

[36]  Fátima Sánchez-Cabo,et al.  Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells , 2011, Nature communications.

[37]  Cole Trapnell,et al.  Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. , 2010, Nature biotechnology.

[38]  Y. Matsuki,et al.  Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells*♦ , 2010, The Journal of Biological Chemistry.

[39]  Xavier Estivill,et al.  SeqBuster, a bioinformatic tool for the processing and analysis of small RNAs datasets, reveals ubiquitous miRNA modifications in human embryonic cells , 2009, Nucleic acids research.

[40]  S. Paternot,et al.  Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation , 2009, Molecular and Cellular Biology.

[41]  Douglas D. Taylor,et al.  Exosomal microRNA: a diagnostic marker for lung cancer. , 2008, Clinical lung cancer.

[42]  Andrew R. Green,et al.  CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.

[43]  Anne-Marie Duchemin,et al.  Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. , 2007, Blood.

[44]  Anne E Carpenter,et al.  A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.

[45]  Yan Geng,et al.  Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.

[46]  A. Papanikolaou,et al.  Cyclin D1 in breast cancer pathogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Massagué,et al.  G1 cell-cycle control and cancer , 2004, Nature.

[48]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[49]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[50]  M. Laiho,et al.  Ectopic expression of Cdk6 circumvents transforming growth factor-β mediated growth inhibition , 2001, Oncogene.

[51]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[52]  J. Taipale,et al.  Hepatocyte Growth Factor Releases Mink Epithelial Cells from Transforming Growth Factor β1-Induced Growth Arrest by Restoring Cdk6 Expression and Cyclin E-Associated Cdk2 Activity , 1999, Molecular and Cellular Biology.